Fosun Pharma
- All
- News
-
China's Fosun Pharma To Import 100 Million BioNTech Vaccine Doses
A Chinese pharmaceutical company said Wednesday it had agreed to buy at least 100 million doses of the coronavirus vaccine from German company BioNTech, subject to Beijing approving its use.
-
Gland Pharma IPO: Here's How To Check Allotment Status
China's Fosun Pharma-backed Gland Pharma's Rs 6,480 crore IPO had managed to sail through, bagging subscription of a mere 2.06 per cent.
-
Gland Pharma IPO Subscribed 22% On Second Day Of Subscription
Gland Pharma's public offer will be the largest pharma IPO in the country, as per estimates. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding.
-
Gland Pharma IPO Opens For Subscription. Here's All You Need To Know
Gland Pharma IPO: The offer consists of a fresh issue of shares worth around Rs 1,250 crore and an offer for sale of more than 3.4 crore shares by Fosun Pharma, Gland Celsus Bio Chemicals, Empower Discretionary Trust and Nilay Discretionary Trust.
-
Gland Pharma Garners Rs 1,944 Crore From Anchor Investors Prior To IPO
The anchor investors include Government of Singapore, Nomura, Goldman Sachs, Morgan Stanley, SBI Mutual Fund, Axis Mutual Fund and SBI Life Insurance and Fidelity.
-
Gland Pharma Gets Nod To Float IPO
The IPO comprises fresh issue of shares amounting to up to Rs 1,250 crore and an offer for sale of more than 3.4 crore shares, draft papers filed with SEBI reveal.
-
Fosun Pharma Completes Largest Ever Chinese Acquisition In India For $1.09 Billion
The Chinese firm decided to scale down its proposed acquisition in Gland Pharma to 74% following objections by government bodies.
-
China's Fosun Pharma To Buy Smaller Stake In Indian Firm
Fosun had previously sought an 86 percent stake in what is set to be China's biggest acquisition in India.
-
Concerns Raised Over Takeover Of Gland Pharma By China's Fosun, Says Report
The closing of the deal, which would be China's largest ever acquisition in India if approved, has now been extended to Sept. 26
-
Fosun Agrees To Buy KKR-Backed Gland Pharma For $1.4 Billion: Report
Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy Gland Pharma - backed by KKR & Co LP - for about $1.4 billion, a person with direct knowledge of the matter said, in India's largest inbound acquisition this year.
-
China's Fosun To Sign Agreement For $1.4 Billion Gland Pharma Buy: Report
Shanghai Fosun Pharmaceutical (Group) Co will sign a definitive agreement on Wednesday to buy a controlling stake in India's Gland Pharma in a $1.4 billion deal, the Economic Times newspaper reported, citing a source with direct knowledge.
-
Fosun Group Returns To M&A With Planned Bid For KKR-Backed Gland Pharma
Shanghai Fosun Pharmaceutical (Group) Co has made a non-binding proposal to buy India's Gland Pharma, which is backed by KKR and valued at up to $1.5 billion, to boost its drug manufacturing and research and development capacity.
-
Beijing Aims to Refill Medicine Chest with 'Made in China' Drugs
China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and ageing population.
-
China's Fosun Pharma To Import 100 Million BioNTech Vaccine Doses
A Chinese pharmaceutical company said Wednesday it had agreed to buy at least 100 million doses of the coronavirus vaccine from German company BioNTech, subject to Beijing approving its use.
-
Gland Pharma IPO: Here's How To Check Allotment Status
China's Fosun Pharma-backed Gland Pharma's Rs 6,480 crore IPO had managed to sail through, bagging subscription of a mere 2.06 per cent.
-
Gland Pharma IPO Subscribed 22% On Second Day Of Subscription
Gland Pharma's public offer will be the largest pharma IPO in the country, as per estimates. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding.
-
Gland Pharma IPO Opens For Subscription. Here's All You Need To Know
Gland Pharma IPO: The offer consists of a fresh issue of shares worth around Rs 1,250 crore and an offer for sale of more than 3.4 crore shares by Fosun Pharma, Gland Celsus Bio Chemicals, Empower Discretionary Trust and Nilay Discretionary Trust.
-
Gland Pharma Garners Rs 1,944 Crore From Anchor Investors Prior To IPO
The anchor investors include Government of Singapore, Nomura, Goldman Sachs, Morgan Stanley, SBI Mutual Fund, Axis Mutual Fund and SBI Life Insurance and Fidelity.
-
Gland Pharma Gets Nod To Float IPO
The IPO comprises fresh issue of shares amounting to up to Rs 1,250 crore and an offer for sale of more than 3.4 crore shares, draft papers filed with SEBI reveal.
-
Fosun Pharma Completes Largest Ever Chinese Acquisition In India For $1.09 Billion
The Chinese firm decided to scale down its proposed acquisition in Gland Pharma to 74% following objections by government bodies.
-
China's Fosun Pharma To Buy Smaller Stake In Indian Firm
Fosun had previously sought an 86 percent stake in what is set to be China's biggest acquisition in India.
-
Concerns Raised Over Takeover Of Gland Pharma By China's Fosun, Says Report
The closing of the deal, which would be China's largest ever acquisition in India if approved, has now been extended to Sept. 26
-
Fosun Agrees To Buy KKR-Backed Gland Pharma For $1.4 Billion: Report
Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy Gland Pharma - backed by KKR & Co LP - for about $1.4 billion, a person with direct knowledge of the matter said, in India's largest inbound acquisition this year.
-
China's Fosun To Sign Agreement For $1.4 Billion Gland Pharma Buy: Report
Shanghai Fosun Pharmaceutical (Group) Co will sign a definitive agreement on Wednesday to buy a controlling stake in India's Gland Pharma in a $1.4 billion deal, the Economic Times newspaper reported, citing a source with direct knowledge.
-
Fosun Group Returns To M&A With Planned Bid For KKR-Backed Gland Pharma
Shanghai Fosun Pharmaceutical (Group) Co has made a non-binding proposal to buy India's Gland Pharma, which is backed by KKR and valued at up to $1.5 billion, to boost its drug manufacturing and research and development capacity.
-
Beijing Aims to Refill Medicine Chest with 'Made in China' Drugs
China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and ageing population.
